DUONEB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Duoneb, and when can generic versions of Duoneb launch?
Duoneb is a drug marketed by Norvium Bioscience and is included in one NDA.
The generic ingredient in DUONEB is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Duoneb
A generic version of DUONEB was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31st, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DUONEB?
- What are the global sales for DUONEB?
- What is Average Wholesale Price for DUONEB?
Summary for DUONEB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 2 |
| DailyMed Link: | DUONEB at DailyMed |
Recent Clinical Trials for DUONEB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospitals Cleveland Medical Center | Phase 1 |
| Shin-hwar Wu | N/A |
US Patents and Regulatory Information for DUONEB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | DUONEB | albuterol sulfate; ipratropium bromide | SOLUTION;INHALATION | 020950-001 | Mar 21, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DUONEB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | DUONEB | albuterol sulfate; ipratropium bromide | SOLUTION;INHALATION | 020950-001 | Mar 21, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DUONEB
See the table below for patents covering DUONEB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2006505486 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2004091536 | ⤷ Sign Up | |
| Canada | 2464735 | SOLUTION D'INHALATION A BASE D'ALBUTEROL ET D'IPRATROPIUM, ET SYSTEME, KIT ET METHODE PERMETTANT DE SOULAGER LES SYMPTOMES DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE (AN ALBUTEROL AND IPRATROPIUM INHALATION SOLUTION, SYSTEM, KIT AND METHOD FOR RELIEVING SYMPTOMS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 03037159 | ⤷ Sign Up | |
| Japan | 2010235617 | METHOD FOR PREPARING ALBUTEROL AND IPRATROPIUM INHALATION SOLUTION FOR RELIEVING SYMPTOM OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND PREPACKAGE TREATMENT SYSTEM | ⤷ Sign Up |
| New Zealand | 552548 | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | ⤷ Sign Up |
| China | 1607940 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
